Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹195 Cr
P/E Ratio
20.69
P/B Ratio
24.52
Industry P/E
37.26
Debt to Equity
131.12
ROE
-183.25 %
ROCE
-4.18 %
Div. Yield
0 %
Book Value
1.68
EPS
1.99
CFO
₹5.61 Cr
EBITDA
₹9.65 Cr
Net Profit
₹-13.04 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kimia Biosciences
| -9.62 | -7.34 | 0.54 | -23.45 | -4.04 | 10.37 | -- |
|
BSE Healthcare
| -6.32 | 0.45 | -0.61 | 22.92 | 19.06 | 22.88 | 9.80 |
|
BSE Small Cap
| -10.19 | 4.03 | -4.86 | 8.30 | 18.78 | 36.03 | 15.82 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
|
|---|---|---|---|---|---|
|
Kimia Biosciences
| 24.35 | -14.42 | -30.19 | 20.33 | 131.58 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 427.50 | 7,030.14 | 25.62 | 12.5 | |
| 5,169.00 | 8,573.83 | 36.24 | 43.77 | |
| 681.25 | 6,630.22 | 75.1 | 4.01 | |
| 630.85 | 5,916.85 | 21.95 | 12.68 |
No Review & Analysis are available.
Laurel Organics Ltd manufactures and sells pharmaceutical-bulk drugs in India. The company offers Benfotiamine, Cilnidipine, Gliclazide, Levosulpride, Rosuvastatin Calcium, Tranexamic Acid, Benidipine, Teneligliptin Hydrate Hydrobromide, Acotiamide,... Citicoline Sodium, Luliconazole, Deflazacort, Voglibose, Oxaceprol, Ursodeoxycholic Acid, Bacitracin Zinc, Isotretinoin, and Tretinoin, as well as vitamin B1, calcium channel blocker, central stimulant/nootropic agent, and choleretic agent. It also provides products for various therapeutic categories, which comprise antidiabetic, antipsychotic, antihyperlipidemic, hemostatic, antihypertensive, antidiabetic, antiemetic, anti-fungal, anti-inflammatory, and anti-acne. The company was incorporated in 1993 and is based in New Delhi, India. Laurel Organics Ltd is a subsidiary of Kimia Biosciences Ltd. Read more
Incorporated
1993
Chairman
Sameer Goel
Managing Director
Sameer Goel
Headquarters
Bhondsi, Haryana
Website
Looking for more details about Kimia Biosciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Kimia Biosciences Ltd stood at ₹ 102 Cr as on 31-Dec-24
The share price of Kimia Biosciences Ltd is ₹41.26 (BSE) as of 22-Apr-2025 12:27 IST. Kimia Biosciences Ltd has given a return of -4.04% in the last 3 years.
Kimia Biosciences Ltd has a market capitalisation of ₹ 195 Cr as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kimia Biosciences Ltd is 24.52 times as on 22-Apr-2025, a 373% premium to its peers’ median range of 5.18 times.
The P/E ratio of Kimia Biosciences Ltd is 20.69 times as on 22-Apr-2025, a 44% discount to its peers’ median range of 37.26 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kimia Biosciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Kimia Biosciences Ltd.
Laurel Organics Ltd manufactures and sells pharmaceutical-bulk drugs in India. The company offers Benfotiamine, Cilnidipine, Gliclazide, Levosulpride, Rosuvastatin Calcium, Tranexamic Acid, Benidipine, Teneligliptin Hydrate Hydrobromide, Acotiamide, Citicoline Sodium, Luliconazole, Deflazacort, Voglibose, Oxaceprol, Ursodeoxycholic Acid, Bacitracin Zinc, Isotretinoin, and Tretinoin, as well as vitamin B1, calcium channel blocker, central stimulant/nootropic agent, and choleretic agent. It also provides products for various therapeutic categories, which comprise antidiabetic, antipsychotic, antihyperlipidemic, hemostatic, antihypertensive, antidiabetic, antiemetic, anti-fungal, anti-inflammatory, and anti-acne. The company was incorporated in 1993 and is based in New Delhi, India. Laurel Organics Ltd is a subsidiary of Kimia Biosciences Ltd.
The promoter of Kimia Biosciences Ltd is SAMEER GOEL. SAMEER GOEL owns 74.94 per cent of the total equity. The chairman of the company is Sameer Goel , and the managing director is Sameer Goel..
There is no promoter pledging in Kimia Biosciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,680
|
|
|
7,005
|
|
|
6,570
|
|
|
6,016
|
| Kimia Biosciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
11.64
|
|
Net Margin(%)
|
8.4
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Kimia Biosciences Ltd was ₹9 Cr.
₹-0.74
(
